ClinicalTrials.gg
CompletedNCT05442047Updated Feb 17, 2026

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

A Phase 2 interventional study of NNC6019-0001 and Placebo (NNC6019-0001) in Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failure. Participants will either get NNC6019-0001 (apotential new medicine) or placebo (a medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting NNC6019-0001 is two times higher than getting placebo. NNC6019-0001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe yet. Participants will get an infusion of the study medicine 13 times, once every 4 weeks. The study will last for about 64 weeks after the first dose of medicine. Participants cannot participate in this study if they have a heart disease other than a heart disease due to TTR amyloidosis.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age greater than or equal to (>=) 18 to less than (\<) 85 years at the time of signing .
  • Have an established diagnosis of Transthyretin amyloid cardiomyopathy (ATTR CM) with either wild-type transhyretin (TTR) or hereditary transthyretin (TTR) genotype as per local standards.
  • Expected to be on stable doses of cardiovascular medical therapy 6 weeks prior to the randomisation visit.
  • Known end-diastolic interventricular septal wall thickness greater than or equal to (>=) 12 millimeters (mm).
  • Presently classified as (NYHA) Class II-III.
  • N-terminal-pro brain natriuretic peptide (NT-proBNP) concentration greater than or equal to (>=) 650 picograms per milliliter (pg/mL) in sinus cardiac rhythm and greater than (>) 1000 pg/mL in atrial fibrillation at screening.
  • Completed greater than or equal to (>=) 150 meters to less than or equal to (\<=) 450 meters on the 6-minute walk test (MWT) at screening.
  • Estimated (eGFR) greater than or equal to (>=) 25 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) at screening.

Exclusion criteria

Exclusion Criteria:

  • Cardiomyopathy not primarily caused by transthyretin amyloid cardiomyopathy transthyretin amyloid cardiomyopathy (ATTR CM), for example, cardiomyopathy due to hypertension, valvular heart disease, or ischemic heart disease.
  • A prior solid organ transplant.
  • Planned solid organ transplant during the study.
  • Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, insitu carcinomas of the cervix, or in-situ/high grade prostatic intraepithelial neoplasia (PIN) or low-grade prostate cancer) within 5 years before screening.
  • Current treatment with calcium channel blockers with conduction system effects (example [e.g.], verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digoxin will only be allowed if required for management of atrial fibrillation with rapid ventricular response.
  • Acute coronary syndrome, unstable angina, stroke, (TIA), coronary revascularization, cardiac valve repair, or major surgery within 3 months of screening.
  • Body weight >120 kilogram (kg) (264.6 pounds [lb]) at screening.
  • History of contrast allergy or adverse reactions to gadolinium-containing agents.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    NNC6019-0001, Dose 1

    Participants will receive dose 1 intravenous (i.v.) infusion of NNC6019-0001 every 4 weeks (Q4W) added to standard of care until week 52.

    Drug: NNC6019-0001

  • Experimental
    NNC6019-0001, Dose 2

    Participants will receive dose 2 i.v. infusion of NNC6019-0001 Q4W added to standard of care until week 52.

    Drug: NNC6019-0001

  • Placebo comparator
    Placebo

    Participants will receive i.v. infusion of placebo (NNC6019-0001) Q4W added to standard of care until week 52.

    Drug: Placebo (NNC6019-0001)

Interventions

  • Participants will receive i.v infusionof NNC6019-0001.

  • DrugPlacebo (NNC6019-0001)

    Participants will receive i.v. infusion of placebo (NNC6019-0001).

06

What researchers measure

Primary outcomes

  1. Change in 6-minute walk test (6-MWT)

    Measured in Meters

    Time frame: From baseline (week 0) to visit 15 (week 52)

  2. Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)

    Measured in Percentage

    Time frame: From baseline (week 0) to visit 15 (week 52)

Secondary outcomes

  1. Change in myocardial extracellular volume (ECV)

    Measured in Percentage (%)-points

    Time frame: From baseline (week 0) to visit 15 (week 52)

  2. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: From baseline (week 0) to visit 15 (week 52)

  3. Change in neuropathy impairment score (NIS)

    NIS is a clinical assessment that tests muscle strength, reflex activity, and sensation of toes and fingers, and can be used to assess neurologic function in hereditary transthyretin amyloid (hATTR). The total NIS score is graded on a scale of 0-244, with a higher score indicating greater impairment.

    Time frame: From baseline (week 0) to visit 15 (week 52)

  4. Change in troponin I

    Measured in nanogram per milliliter (ng/mL)

    Time frame: From baseline (week 0) to visit 15 (week 52)

  5. Change in global longitudinal strain (GLS) on echocardiography

    Measured in Percentage (%)-points

    Time frame: From baseline (week 0) to visit 15 (week 52)

  6. Number of treatment emergent adverse events

    Measured as Events

    Time frame: From baseline (week 0) to visit 16 (week 64)

  7. Time to occurrence of all-cause mortality

    Measured in Weeks

    Time frame: From baseline (week 0) to visit 16 (week 64)

  8. Number of cardiovascular (CV) events comprising hospitalisation due to CV events or urgent heart failure visits

    Measured as Events

    Time frame: From baseline (week 0) to visit 16 (week 64)

07

Study locations

39 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Cedars-Sinai Medical Center_Los Angeles
    Beverly Hills, California 90211, United States
  • Stanford Hlth Cre-Boswell Clin
    Stanford, California 94305, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • NW Univ-Bluhm Cardiovasc Inst
    Evanston, Illinois 60208, United States
  • Univ of MD Schl of Med
    Baltimore, Maryland 21201, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Oregon Hlth Sci Univ-Portland
    Portland, Oregon 97239-4501, United States
  • University of Calgary_Cardiology
    Calgary, Alberta T2N 4Z6, Canada
  • Ctr for Cardiovascular Innovation
    Vancouver, British Columbia V5Z 1M9, Canada
  • II. interni klinika VFN - Kardiologie a angiologie
    Prague, 12808, Czechia
  • Ap-Hp-Hopital Henri Mondor
    Créteil, 94000, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
    Toulouse, 31059, France
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
    Toulouse Cedex 9 TSA 50032, 31059, France
  • UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie
    Heidelberg, 69120, Germany
  • LMU Klinikum München Klinik und Poliklinik 1
    München, 81377, Germany
  • Universitätsklinikum Münster - Klinik für Kardiologie I
    Münster, 48149, Germany
  • Universitatsklinikum Wurzburg AöR
    Würzburg, 97078, Germany
  • Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz
    Würzburg, 97078, Germany
  • Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare
    Pisa, Pi 56124, Italy
  • Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo
    Pavia, PV 27100, Italy
  • Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology
    Fukuoka, 807-8556, Japan
  • Hospital of the University of Occupational and Environmental Health
    Fukuoka, 807-8556, Japan
  • Hiroshima University hospital, Cardiovascular Medicine
    Hiroshima, 734-8551, Japan
  • Hiroshima University hospital_Cardiovascular Medicine
    Hiroshima, 734-8551, Japan
  • Kumamoto University Hospital, Cardiovascular Medicine
    Kumamoto-shi, Kumamoto, 860-8556, Japan
  • Shinshu University Hospital, Department of Neurology
    Nagano, 390-8621, Japan
  • Nagasaki University Hospital, Cardiovascular Medicine
    Nagasaki, 852-8501, Japan
  • Okayama University Hospital_Cardiovascular Medicine
    Okayama-shi, Okayama, 700-8558, Japan
  • UMC Groningen afdeling Cardiologie
    Groningen, 9713 GZ, Netherlands
  • UMC Groningen
    Groningen, 9713 GZ, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Hospital da Senhora da Oliveira - Guimarães
    Guimarães, 4835-044, Portugal
  • ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
    Guimarães, 4835-044, Portugal
  • Unidade Local de Saude do Alto Ave, E.P.E.
    Guimarães, 4835-044, Portugal
  • ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
    Vila Real, 5000-508, Portugal
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
08

References and documents

Publications

  • Fontana M, Garcia-Pavia P, Grogan M, Shah SJ, Engelmann MDM, Hovingh GK, Kristen AV, Lim-Watson MZ, Malling B, Kar S, Revanna M, Sarswat N, Tsujita K, Alexander KM, Maurer MS. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27;153(4):214-225. doi: 10.1161/CIRCULATIONAHA.125.077304. Epub 2025 Nov 10. PubMed 41212997 ↗
  • Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2025 Mar;32(1):14-21. doi: 10.1080/13506129.2024.2420809. Epub 2024 Oct 29. PubMed 39472768 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2025, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 1, 2022
StartActual
Aug 2, 2022
Primary completionActual
Feb 17, 2025
CompletionActual
May 13, 2025
Results delay requested
Feb 13, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05442047
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Aug 2, 2022
Primary completion
Feb 17, 2025
Completion
May 13, 2025
Last update
Feb 17, 2026

Study contacts

Clinical Transparency 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC6019-0001

Start the discussion